,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2018-01-11 22:33:00,The Zacks Research Daily presents the best research output of our analyst team.,0.6325156092643738,0.012341027148067951,0.35514333844184875,positive,0.6201745867729187
1,2018-01-11 22:33:00,"Today's Research Daily features new research reports on 16 major stocks, including Home Depot (HD), CVS Health (CVS) and Biogen (BIIB).",0.04426157847046852,0.0072823152877390385,0.9484561681747437,neutral,0.03697926178574562
2,2018-01-11 22:33:00,These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.,0.054846275597810745,0.007339245639741421,0.937814474105835,neutral,0.04750702902674675
3,2018-01-11 22:33:00,"You can see all of today's research reports here >>>

Home Depot 's shares have gained +44.2% over the last one year, compared with the +37.8% gain of the Zacks Retail Building Products industry, backed by its five-year long trend of beating earnings estimates.",0.9549513459205627,0.028083298355340958,0.0169653482735157,positive,0.9268680214881897
4,2018-01-11 22:33:00,"The company delivered bottom-line beat in third-quarter fiscal 2017, while sales topped estimates for the fifth straight quarter.",0.9310442209243774,0.028892597183585167,0.04006313532590866,positive,0.9021516442298889
5,2018-01-11 22:33:00,"Results gained from strength in core business as well as relentless focus on affording innovative products, boosting interconnected customer experience and driving productivity.",0.9371642470359802,0.014141994528472424,0.04869364947080612,positive,0.9230222702026367
6,2018-01-11 22:33:00,Steady housing market recovery and strong customer demand also remained tailwinds.,0.41334089636802673,0.4791700541973114,0.10748894512653351,negative,-0.06582915782928467
7,2018-01-11 22:33:00,"Home Depot raised top and bottom-line guidance for fiscal 2017, based on the solid year-to-date performance and anticipated gains from hurricane recovery activities.",0.8432254195213318,0.019581224769353867,0.13719335198402405,positive,0.82364422082901
8,2018-01-11 22:33:00,"While hurricane-related activities aided comps growth, gross margins on such sales were significantly below average.",0.020050186663866043,0.9636198878288269,0.016329914331436157,negative,-0.9435697197914124
9,2018-01-11 22:33:00,"This led to a decline in gross margin, which is likely to continue in fiscal 2017.",0.018560631200671196,0.968575656414032,0.012863771989941597,negative,-0.9500150084495544
10,2018-01-11 22:33:00,"Moreover, competition from online retailers may impact performance.",0.03194781765341759,0.7816116809844971,0.1864406019449234,negative,-0.7496638894081116
11,2018-01-11 22:33:00,(You can read the full research report on Home Depot here >>> ).,0.012610534206032753,0.013505421578884125,0.973884105682373,neutral,-0.0008948873728513718
12,2018-01-11 22:33:00,Shares of CVS Health have outperformed the Zacks Drug Stores industry over the last six months gaining +1.4% vs. a decline of -2.3%.,0.5148248672485352,0.46261778473854065,0.022557364776730537,positive,0.05220708250999451
13,2018-01-11 22:33:00,The company has been gaining on the back of strong Pharmacy Services segment that benefited from the upside in the Specialty Pharmacy.,0.9563586115837097,0.018449340015649796,0.025191960856318474,positive,0.9379092454910278
14,2018-01-11 22:33:00,"The Zacks analyst is also encouraged to note that, despite a soft bottom-line scenario, the company reiterated its earnings outlook for 2017 indicating chances of recovery ahead.",0.9403064250946045,0.02315814420580864,0.03653545305132866,positive,0.9171482920646667
15,2018-01-11 22:33:00,CVS Health's on-going strong 2018 PBM selling season is another upside.,0.7627326250076294,0.02868000976741314,0.2085873782634735,positive,0.7340525984764099
16,2018-01-11 22:33:00,"Also, CVS Health's plan to acquire Aetna might change the Healthcare landscape in the United States.",0.5872417688369751,0.022108320146799088,0.3906499445438385,positive,0.5651334524154663
17,2018-01-11 22:33:00,"On the flip side, the company has been suffering from softness in Retail/LTC business and a weak margin scenario.",0.02275834046304226,0.9587101340293884,0.01853158138692379,negative,-0.9359517693519592
18,2018-01-11 22:33:00,(You can read the full research report on CVS Health here >>> ).,0.01250061672180891,0.012877383269369602,0.9746220707893372,neutral,-0.00037676654756069183
19,2018-01-11 22:33:00,Biogen 's shares have outperformed the Zacks Biomedicals and Genetics industry over the last one year (+17.0% vs. +0.9%).,0.4327930808067322,0.543226420879364,0.023980556055903435,negative,-0.11043334007263184
20,2018-01-11 22:33:00,Biogen has a strong position in the MS market.,0.761054515838623,0.010908580385148525,0.22803685069084167,positive,0.7501459121704102
21,2018-01-11 22:33:00,"The Zacks analyst also likes its efforts to diversify beyond MS to other areas like Alzheimer's, Parkinson's, stroke, among others.",0.7859803438186646,0.011396436020731926,0.2026231437921524,positive,0.7745839357376099
22,2018-01-11 22:33:00,"Meanwhile, Spinraza has witnessed strong patient uptake in the U.S. and internationally.",0.949787437915802,0.014126008376479149,0.03608658164739609,positive,0.9356614351272583
23,2018-01-11 22:33:00,"However, Tecfidera is witnessing slight decline in U.S. patient demand due to increasing competition from oral medicines and a slowdown in the overall MS market.",0.016741326078772545,0.9692510366439819,0.014007645659148693,negative,-0.9525097012519836
24,2018-01-11 22:33:00,"Meanwhile, the recent Ocrevus launch by Roche is beginning to have a negative impact on MS franchise sales in the U.S. At the call, the company said that seasonality and continued competitive pressure from Ocrevus' launch will hurt the performance of its MS franchise in Q4.",0.01895609311759472,0.9646577835083008,0.016386205330491066,negative,-0.9457017183303833
25,2018-01-11 22:33:00,Estimate movement has been mixed ahead of Q4 earnings results.,0.038035109639167786,0.9041435718536377,0.0578213594853878,negative,-0.8661084771156311
26,2018-01-11 22:33:00,The company has a positive record of earnings surprises in recent quarters.,0.9442597031593323,0.02228577248752117,0.03345456346869469,positive,0.9219739437103271
27,2018-01-11 22:33:00,(You can read the full research report on Biogen here >>> ).,0.013879170641303062,0.012286399491131306,0.9738344550132751,neutral,0.0015927711501717567
28,2018-01-11 22:33:00,"Other noteworthy reports we are featuring today include Raytheon (RTN), Alphabet (GOOGL) and Western Digital (WDC).",0.03681949898600578,0.0054509807378053665,0.9577295184135437,neutral,0.03136851638555527
29,2018-01-11 22:33:00,"Zacks Editor-in-Chief Goes ""All In"" on This Stock

Full disclosure, Kevin Matras now has more of his own money in one particular stock than in any other.",0.046605318784713745,0.02256212756037712,0.93083256483078,neutral,0.024043191224336624
30,2018-01-11 22:33:00,He believes in its short-term profit potential and also in its prospects to more than double by 2019.,0.9215595126152039,0.014699761755764484,0.06374071538448334,positive,0.9068597555160522
31,2018-01-11 22:33:00,Today he reveals and explains his surprising move in a new Special Report.,0.3703147768974304,0.012097598053514957,0.617587685585022,neutral,0.35821717977523804
32,2018-01-11 22:33:00,Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings.,0.1108352467417717,0.007436841260641813,0.881727933883667,neutral,0.1033984050154686
33,2018-01-11 22:33:00,He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trendsand Earnings Previewreports.,0.026142945513129234,0.011532393284142017,0.9623246192932129,neutral,0.014610552228987217
34,2018-01-11 22:33:00,"If you want an email notification each time Sheraz publishes a new article, please click here>>>

While Encana's strong focus on the Montney and Permian plays will drive production growth, the Zacks analyst is concerned about the firm's negative free cash flow over the past few quarters.",0.029950782656669617,0.9372789263725281,0.032770343124866486,negative,-0.9073281288146973
35,2018-01-11 22:33:00,"Per a Zacks analyst, Nordson's Sonoscan acquisition will solidify its test and inspection business while Infiniti Dosing's PCP products buyout will expand the dispensing and dosing business.",0.923567533493042,0.013544228859245777,0.0628882572054863,positive,0.9100233316421509
36,2018-01-11 22:33:00,"Per the Zacks analyst, new product additions will enhance the Western Digital's existing product portfolio and aid it in securing a strong foothold in the global SSD market.",0.951521098613739,0.015196375548839569,0.03328260779380798,positive,0.9363247156143188
37,2018-01-11 22:33:00,"The Zacks analyst believes that Alphabet's focus on diversification artificial intelligence, Android OS and hardware is a positive.",0.7858090996742249,0.011584999039769173,0.2026059478521347,positive,0.7742241024971008
38,2018-01-11 22:33:00,"Per the Zacks analyst, a number of profitable acquisitions like NetSpend, TransFirst along with its consistent focus on new product initiatives, technology modernization have driven top line growth.",0.9313205480575562,0.01350354589521885,0.05517596751451492,positive,0.9178169965744019
39,2018-01-11 22:33:00,"Per the Zacks analyst, solid online and in-store traffic, alongside momentum at AE and Aerie brands should drive sales.",0.9545062780380249,0.019758835434913635,0.025734927505254745,positive,0.9347474575042725
40,2018-01-11 22:33:00,"Per the Zacks analyst, E*TRADE 's efforts to enhance trading business by introduction of new brokerage products and services might support its growth.",0.9538611769676208,0.015282873995602131,0.030855990946292877,positive,0.9385783076286316
41,2018-01-11 22:33:00,"Per the Zacks analyst, foreign military contracts continue to be a vital growth driver for Raytheon.",0.9117763042449951,0.013177018612623215,0.07504678517580032,positive,0.8985992670059204
42,2018-01-11 22:33:00,Also the company has been witnessing strong demand for its varied kind of surveillance radars.,0.9353107810020447,0.014615423046052456,0.050073761492967606,positive,0.9206953644752502
43,2018-01-11 22:33:00,Toyota is partnering with technology companies to raise its hold in the electric & self-driving cars market.,0.93573397397995,0.016731616109609604,0.047534313052892685,positive,0.91900235414505
44,2018-01-11 22:33:00,"Per the Zacks analyst, this will help meet rising demand for multi-faceted transportation.",0.9269251823425293,0.014681179076433182,0.05839360132813454,positive,0.9122440218925476
45,2018-01-11 22:33:00,The Zacks analyst is encouraged by Brinker's operational efficiencies like remodeling of outlets.,0.8352005481719971,0.014195564202964306,0.15060387551784515,positive,0.8210049867630005
46,2018-01-11 22:33:00,Other sales boosting efforts like menu innovation and digital advancement should drive growth.,0.9128210544586182,0.014235819689929485,0.07294312864542007,positive,0.8985852599143982
47,2018-01-11 22:33:00,"Per the Zacks analyst, rise in supply of residential housing assets in Mid-America Apartment's key markets will likely lower rent and occupancy growth.",0.031813882291316986,0.9447061419487,0.02348005212843418,negative,-0.9128922820091248
48,2018-01-11 22:33:00,"Also, higher interest rates will hamper growth.",0.01909365877509117,0.9568413496017456,0.024064945057034492,negative,-0.9377477169036865
49,2018-01-11 22:33:00,"Per the Zacks analyst, A. O. Smith is struggling with high selling, general & administrative expenses in China.",0.023168155923485756,0.9505413174629211,0.02629055269062519,negative,-0.9273731708526611
50,2018-01-11 22:33:00,Continuous rise in steel prices and intensive competition also remain a concern.,0.06141986697912216,0.06387943029403687,0.8747007250785828,neutral,-0.0024595633149147034
51,2018-01-11 22:33:00,"The Zacks analyst is concerned that Teva is facing significant challenges like generic competition for Copaxone, pricing erosion in the U.S. generics business and a massive debt load.",0.02852516807615757,0.9263160824775696,0.04515877366065979,negative,-0.8977909088134766
52,2018-01-11 22:33:00,Want the latest recommendations from Zacks Investment Research?,0.03539300337433815,0.011573811061680317,0.9530332088470459,neutral,0.023819193243980408
53,2018-01-11 22:33:00,"Today, you can download 7 Best Stocks for the Next 30 Days.",0.05069372057914734,0.007019792217761278,0.9422864317893982,neutral,0.04367392882704735
54,2018-01-11 22:33:00,"Click to get this free report

To read this article on Zacks.com click here.",0.020684564486145973,0.03315984085202217,0.9461556077003479,neutral,-0.012475276365876198
55,2018-01-11 22:33:00,"The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.010204566642642021,0.015637893229722977,0.9741575717926025,neutral,-0.0054333265870809555
